Zobrazeno 1 - 10
of 59
pro vyhledávání: '"Marie A, Holahan"'
Autor:
Jeanine E. Ballard, Parul S. Pall, Joshua Vardigan, Fuqiang Zhao, Marie A. Holahan, Xiaoping Zhou, Nina Jochnowitz, Richard L. Kraus, Rebecca M. Klein, Darrell A. Henze, Andrea K. Houghton, Christopher S. Burgey, Christopher Gibson, Arie Struyk
Publikováno v:
Frontiers in Pharmacology, Vol 12 (2021)
MK-2075 is a small-molecule selective inhibitor of the NaV1.7 channel investigated for the treatment of postoperative pain. A translational strategy was developed for MK-2075 to quantitatively interrelate drug exposure, target modulation, and the des
Externí odkaz:
https://doaj.org/article/b6acf3025c844a49ac376ac7097521ef
Autor:
Fuqiang Zhao, Marie A Holahan, Xiaohai Wang, Jason M Uslaner, Andrea K Houghton, Jeffrey L Evelhoch, Christopher T Winkelmann, Catherine D G Hines
Publikováno v:
PLoS ONE, Vol 13, Iss 6, p e0198395 (2018)
Studies in rodents show that olfactory processing in the principal neurons of olfactory bulb (OB) and piriform cortex (PC) is controlled by local inhibitory interneurons, and glutamate NMDA receptor plays a role in this inhibitory control. It is not
Externí odkaz:
https://doaj.org/article/86d37ac6421f4801aaa22f315635e899
Autor:
Mary Wolf, Idriss Bennacef, Hyking Haley, Terence G. Hamill, G Wesolowski, Shawn J. Stachel, Le T. Duong, Mangay Williams, Diane J. Posavec, Mona Purcell, Eric D. Hostetler, Jeffrey L. Evelhoch, Marie A. Holahan, Daniel Rubins, Laura S. Lubbers, Kerry Riffel
Publikováno v:
Journal of Labelled Compounds and Radiopharmaceuticals. 64:159-167
The cathepsin K (CatK) enzyme is abundantly expressed in osteoclasts, and CatK inhibitors have been developed for the treatment of osteoporosis. In our effort to support discovery and clinical evaluations of a CatK inhibitor, we sought to discover a
Autor:
Brett Connolly, Stacey O'Malley, Michael Klimas, Jeffrey L. Evelhoch, Daniel Rubins, Caroline Ekblad, Marie A. Holahan, Mona Purcell, Paul McQuade, Eric D. Hostetler, Dinko Gonzalez Trotter, Fredrik Y. Frejd, Shu-An Lin, Xiangjun Meng, Pär Eklund, Joel Lindgren, Liza Gantert, Hyking Haley, Krista L. Getty
Publikováno v:
Molecular Imaging and Biology. 23:241-249
In vivo imaging of programmed death ligand 1 (PD-L1) during immunotherapy could potentially monitor changing PD-L1 expression and PD-L1 expression heterogeneity within and across tumors. Some protein constructs can be used for same-day positron emiss
Autor:
John A. Morrow, Robert Mazzola, Cristian Salinas, Eric D. Hostetler, Stefania Risso, Fiona Thomson, Tjerk Bueters, Nicholas B. Hastings, Jenny Wai, Sony Agrawal, Liza Gantert, Brian C. Magliaro, Paul McQuade, Zhizhen Zeng, Marie A. Holahan, David Hesk, Melissa Egbertson, Jeffrey W. Schubert, Ling Tong, Robert Gomez, Jongrock Kong, Aniket Joshi, Frederick J. Monsma, David M. Tellers, Kristen L.G. Jones, Jason M. Uslaner, Jing Liao, Patricia Miller, Michelle Smith, Oleg Selyutin, Kerry Riffel, Xiaolei Gao, Scott T. Harrison, Zhaoyang Meng, James Mulhearn, Michael Man-Chu Lo, Wenping Li, Michael T. Rudd, Barbara Hanney, Mona Purcell, Jianming Bao, Hyking Haley
Publikováno v:
Journal of Medicinal Chemistry. 63:2411-2425
The measurement of receptor occupancy (RO) using positron emission tomography (PET) has been instrumental in guiding discovery and development of CNS directed therapeutics. We and others have investigated muscarinic acetylcholine receptor 4 (M4) posi
Autor:
Eric Messina, Marie A. Holahan, Lufei Hu, Xiaoyan Zhou, Gayathri Swaminath, Catherine D. G. Hines, Fuqiang Zhao
Publikováno v:
NMR in Biomedicine. 34
Kidney diseases such as acute kidney injury, diabetic nephropathy and chronic kidney disease (CKD) are related to dysfunctions of the microvasculature in the kidney causing a decrease in renal blood perfusion (RBP). Pharmacological intervention to im
Autor:
Richard L. Kraus, Ronald M. Kim, Jeanine E. Ballard, Thomas J. Greshock, Andrea K. Houghton, Michelle K. Clements, Marie A. Holahan, Andrew Danziger, Christopher S. Burgey, Yuxing Li, Mark E. Layton, Jordi Serra, Parul S. Pall, Rebecca M. Klein, Joshua D. Vardigan, Dan Zhou, Fuqiang Zhao, Christopher Daley, Darrell A. Henze
Publikováno v:
Science Translational Medicine. 13
Humans with loss-of-function mutations in the Nav1.7 channel gene (SCN9A) show profound insensitivity to pain, whereas those with gain-of-function mutations can have inherited pain syndromes. Therefore, inhibition of the Nav1.7 channel with a small m
Autor:
Michael Klimas, Yuchuan Wang, Elisabeth G.E. de Vries, Michael Judo, Shuli Zhang, Idriss Bennacef, Marie A. Holahan, SuChun Hseih, Wolfgang Seghezzi, Marjolijn N. Lub-de Hooge, Hyking Haley, Daniel Rubins, Jeffrey L. Evelhoch, Eric D. Hostetler, Wenping Li, Elly L van der Veen, Mona Purcell, Liza Gantert
Publikováno v:
Molecular Imaging and Biology
Molecular Imaging and Biology, 23. SPRINGER
Molecular Imaging and Biology, 23. SPRINGER
Purpose Programmed cell death-1 receptor (PD-1) and its ligand (PD-L1) are the targets for immunotherapy in many cancer types. Although PD-1 blockade has therapeutic effects, the efficacy differs between patients. Factors contributing to this variabi
Autor:
Joshua D. Vardigan, Christopher R. Gibson, Darrell A. Henze, Andrea K. Houghton, Marie A. Holahan, Fuqiang Zhao, Parul S. Pall, Richard L. Kraus, Yuxing Li, Jeanine E. Ballard, Christopher S. Burgey
Publikováno v:
Pharmaceutical Research
Purpose This work describes a staged approach to the application of pharmacokinetic-pharmacodynamic (PK-PD) modeling in the voltage-gated sodium ion channel (NaV1.7) inhibitor drug discovery effort to address strategic questions regarding in vitro to
Autor:
Idriss, Bennacef, Daniel, Rubins, Kerry, Riffel, Mangay, Williams, Diane J, Posavec, Marie A, Holahan, Mona L, Purcell, Hyking D, Haley, Mary, Wolf, Shawn J, Stachel, Laura S, Lubbers, Gregg A, Wesolowski, Le T, Duong, Terence G, Hamill, Jeffrey L, Evelhoch, Eric D, Hostetler
Publikováno v:
Journal of labelled compoundsradiopharmaceuticalsREFERENCES. 64(4)
The cathepsin K (CatK) enzyme is abundantly expressed in osteoclasts, and CatK inhibitors have been developed for the treatment of osteoporosis. In our effort to support discovery and clinical evaluations of a CatK inhibitor, we sought to discover a